• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Symptoms of anxiety and depression in patients with primary hyperhidrosis and its association with the result of clinical treatment with oxybutynin.原发性多汗症患者的焦虑和抑郁症状及其与奥昔布宁临床治疗效果的关系。
Clinics (Sao Paulo). 2021 Jun 28;76:e2892. doi: 10.6061/clinics/2021/e2892. eCollection 2021.
2
Quality of life before hyperhidrosis treatment as a predictive factor for oxybutynin treatment outcomes in palmar and axillary hyperhidrosis.多汗症治疗前的生活质量作为奥昔布宁治疗手掌和腋窝多汗症疗效的预测因素。
Ann Vasc Surg. 2014 May;28(4):970-6. doi: 10.1016/j.avsg.2013.07.032. Epub 2013 Dec 11.
3
Long-term results of the treatment of primary hyperhidrosis with oxybutynin: follow-up of 1,658 cases.奥昔布宁治疗原发性多汗症的长期疗效:1658 例随访。
Int J Dermatol. 2020 Jun;59(6):709-715. doi: 10.1111/ijd.14872. Epub 2020 Apr 16.
4
The use of oxybutynin for treating axillary hyperhidrosis.奥昔布宁用于治疗腋窝多汗症。
Ann Vasc Surg. 2011 Nov;25(8):1057-62. doi: 10.1016/j.avsg.2011.06.007.
5
Efficacy and quality of life outcomes of oxybutynin for treating palmar hyperhidrosis in children younger than 14 years old.奥昔布宁治疗14岁以下儿童手掌多汗症的疗效及生活质量结果
Pediatr Dermatol. 2014 Jan-Feb;31(1):48-53. doi: 10.1111/pde.12142. Epub 2013 Apr 29.
6
A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis.一项奥昔布宁治疗手掌和腋窝多汗症的随机安慰剂对照试验。
J Vasc Surg. 2012 Jun;55(6):1696-700. doi: 10.1016/j.jvs.2011.12.039. Epub 2012 Feb 16.
7
Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin.局灶性原发性多汗症罕见部位的治疗:使用奥昔布宁进行药物治疗的经验
Clinics (Sao Paulo). 2014 Sep;69(9):608-14. doi: 10.6061/clinics/2014(09)06.
8
Videothoracoscopic Sympathectomy Results after Oxybutynin Chloride Treatment Failure.奥昔布宁治疗失败后的电视胸腔镜交感神经切除术结果
Ann Vasc Surg. 2017 Aug;43:283-287. doi: 10.1016/j.avsg.2017.01.018. Epub 2017 May 3.
9
Combination of topical agents and oxybutynin as a therapeutic modality for patients with both osmidrosis and hyperhidrosis.外用药物与奥昔布宁联合使用作为治疗腋臭和多汗症患者的一种治疗方式。
Rev Assoc Med Bras (1992). 2018 Feb;64(2):127-132. doi: 10.1590/1806-9282.64.02.127.
10
Real-life experience with oral oxybutynin long-term continuous therapy in severe hyperhidrosis and systematic review of the literature.真实世界中口服羟丁宁长期连续治疗重度多汗症的经验及文献系统评价。
Dermatol Ther. 2021 Mar;34(2):e14832. doi: 10.1111/dth.14832. Epub 2021 Feb 11.

引用本文的文献

1
Continuous evaluation of exosomatic electrodermal activity in patients with primary palmoplantar hyperhidrosis.原发性掌跖多汗症患者体表皮肤电活动的持续评估。
Einstein (Sao Paulo). 2024 Dec 9;22:eAO1152. doi: 10.31744/einstein_journal/2024AO1152. eCollection 2024.
2
Treatment of Primary Axillary Hyperhidrosis with Two Doses of Botulinum Toxin A-Observational Study.Botulinum Toxin A in the Treatment of Primary Axillary Hyperhidrosis: A Double-Dose Cohort Study.
Toxins (Basel). 2024 Jul 16;16(7):320. doi: 10.3390/toxins16070320.
3
The reliability and validity of a developed anxiety scale specific to primary focal hyperhidrosis symptoms.一种专门针对原发性局限性多汗症症状所开发的焦虑量表的信度和效度。
Biopsychosoc Med. 2024 Jun 4;18(1):14. doi: 10.1186/s13030-024-00310-y.
4
Pharmacovigilance-based drug repurposing: searching for putative drugs with hypohidrosis or anhidrosis adverse events for use against hyperhidrosis.基于药物警戒的药物再利用:寻找具有少汗或无汗不良事件的潜在药物,用于治疗多汗症。
Eur J Med Res. 2023 Feb 24;28(1):95. doi: 10.1186/s40001-023-01048-z.

本文引用的文献

1
Long-term results of the treatment of primary hyperhidrosis with oxybutynin: follow-up of 1,658 cases.奥昔布宁治疗原发性多汗症的长期疗效:1658 例随访。
Int J Dermatol. 2020 Jun;59(6):709-715. doi: 10.1111/ijd.14872. Epub 2020 Apr 16.
2
Comparative analysis of the results of videothoracoscopic sympathectomy in the treatment of hyperhidrosis in adolescent patients.青少年多汗症患者胸腔镜交感神经切断术治疗结果的对比分析。
J Pediatr Surg. 2020 Mar;55(3):418-424. doi: 10.1016/j.jpedsurg.2019.11.004. Epub 2020 Jan 23.
3
Association of Primary Hyperhidrosis with Depression and Anxiety: A Systematic Review.原发性多汗症与抑郁和焦虑的关联:一项系统综述。
Acta Derm Venereol. 2020 Jan 30;100(1):adv00044. doi: 10.2340/00015555-3393.
4
Impact of Video-Assisted Thoracoscopic Sympathectomy and Related Complications on Quality of Life According to the Level of Sympathectomy.根据交感神经切除术的水平,电视辅助胸腔镜交感神经切除术及其相关并发症对生活质量的影响。
Ann Vasc Surg. 2020 Feb;63:63-67.e1. doi: 10.1016/j.avsg.2019.07.018. Epub 2019 Oct 16.
5
A comparative study of thoracoscopic sympathectomy for the treatment of hand sweating.胸腔镜交感神经切除术治疗手部多汗症的对比研究
J Thorac Dis. 2019 Aug;11(8):3336-3340. doi: 10.21037/jtd.2019.08.18.
6
Analysis of the Results of Videotoracoscopic Sympathectomy in the Treatment of Hyperhidrosis in Patients 40 Years or Older.40岁及以上患者胸腔镜交感神经切除术治疗多汗症的结果分析
Ann Vasc Surg. 2020 May;65:107-112. doi: 10.1016/j.avsg.2019.04.024. Epub 2019 Sep 5.
7
Relationship between depression scores and degree of skin perspiration: A novel cross-sectional study.抑郁评分与皮肤出汗程度的关系:一项新的横断面研究。
Int Wound J. 2019 Feb;16(1):139-143. doi: 10.1111/iwj.13004. Epub 2018 Sep 24.
8
Impact of Thoracoscopic T2 Sympathectomy on Patients With Primary Palmar and Axillary Hyperhidrosis.胸腔镜 T2 交感神经切断术对原发性手掌和腋窝多汗症患者的影响。
Ann Thorac Surg. 2018 Oct;106(4):1032-1037. doi: 10.1016/j.athoracsur.2018.05.023. Epub 2018 Jun 7.
9
Long-Term Impact of Endoscopic Thoracic Sympathectomy for Primary Palmar Hyperhidrosis.胸腔镜胸交感神经切断术治疗原发性手掌多汗症的长期影响。
Ann Thorac Surg. 2018 Oct;106(4):1008-1012. doi: 10.1016/j.athoracsur.2018.04.063. Epub 2018 Jun 7.
10
Endoscopic thoracic sympathectomy for primary focal hyperhidrosis: impact on psycho-social symptomatology and psychotropic medication use.胸腔镜胸交感神经切断术治疗原发性局限性多汗症:对精神社会症状和精神药物使用的影响。
Eur J Cardiothorac Surg. 2018 Nov 1;54(5):904-911. doi: 10.1093/ejcts/ezy211.

原发性多汗症患者的焦虑和抑郁症状及其与奥昔布宁临床治疗效果的关系。

Symptoms of anxiety and depression in patients with primary hyperhidrosis and its association with the result of clinical treatment with oxybutynin.

机构信息

Divisao de Psicologia, Instituto Central, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.

Disciplina de Cirurgia Vascular e Endovascular, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.

出版信息

Clinics (Sao Paulo). 2021 Jun 28;76:e2892. doi: 10.6061/clinics/2021/e2892. eCollection 2021.

DOI:10.6061/clinics/2021/e2892
PMID:34190853
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8221552/
Abstract

OBJECTIVES

Studies have identified correlations between the psychological characteristics of individuals with primary hyperhidrosis (HH), the degree of sweating, and the quality of life (QoL). This study aimed to evaluate the prevalence of anxiety and depression symptoms in patients with HH before and after oxybutynin treatment.

METHODS

Data were collected from 81 patients. Palmar or axillary HH was the most frequent complaint (84.0%). All patients were evaluated before the medication was prescribed and after five weeks of treatment. The Beck Depression Inventory and Beck Anxiety Inventory were used to evaluate depression and anxiety.

RESULTS

Improvement in HH occurred in 58 patients (71.6%), but there was no improvement in 23 patients (28.4%). The QoL before treatment in all patients was either "poor" or "very poor." Patients who experienced improvement in sweating rates also experienced a greater improvement in QoL than patients who did not experience improvement in sweating at the main site (87.9% vs. 34.7%) (p<0.001). A total of 19.7% of patients showed an improvement in their level of depression, and a total of 46.9% of patients exhibited improvements in their level of anxiety. A significant correlation was observed between sweating and anxiety (p=0.015).

CONCLUSION

Patients with HH who experienced improvements in sweating immediately after treatment with oxybutynin exhibited small improvements in their levels of depression and significant improvements in their levels of anxiety and QoL.

摘要

目的

研究已经确定了原发性多汗症(HH)患者的心理特征、出汗程度和生活质量(QoL)之间的相关性。本研究旨在评估羟丁宁治疗前后 HH 患者焦虑和抑郁症状的患病率。

方法

共收集了 81 例患者的数据。手掌或腋窝 HH 是最常见的抱怨(84.0%)。所有患者在开处方前和治疗五周后均进行了评估。采用贝克抑郁量表和贝克焦虑量表评估抑郁和焦虑。

结果

58 例(71.6%)患者 HH 得到改善,但 23 例(28.4%)患者没有改善。所有患者在治疗前的 QoL 均为“差”或“很差”。出汗率改善的患者比主要部位出汗未改善的患者 QoL 改善更大(87.9%比 34.7%)(p<0.001)。19.7%的患者抑郁水平有所改善,46.9%的患者焦虑水平有所改善。出汗与焦虑之间存在显著相关性(p=0.015)。

结论

羟丁宁治疗后立即出汗改善的 HH 患者,其抑郁水平略有改善,焦虑水平和 QoL 显著改善。